WBR0501: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{{WBRQuestion |QuestionAuthor=Gonzalo A. Romero, M.D. [mailto:gromero@wikidoc.org] |ExamType=USMLE Step 1 |MainCategory=Pathology, Pathophysiology, ...") |
No edit summary |
||
Line 63: | Line 63: | ||
|AnswerD=Increases AP duration, increases ERP, increases QT interval. Acts on both atria and ventricle. | |AnswerD=Increases AP duration, increases ERP, increases QT interval. Acts on both atria and ventricle. | ||
|AnswerDExp=<font color=" | |AnswerDExp=<font color="red">'''Incorrect.'''</font> This mechanism corresponds to class IA sodium channel blockers. | ||
|AnswerE=Decreases SA and AV nodal activity. Increases the PR interval. Decreases the slope of phase 4. | |AnswerE=Decreases SA and AV nodal activity. Increases the PR interval. Decreases the slope of phase 4. |
Revision as of 03:16, 23 September 2013
Author | [[PageAuthor::Gonzalo A. Romero, M.D. [1]]] |
---|---|
Exam Type | ExamType::USMLE Step 1 |
Main Category | MainCategory::Pathology, MainCategory::Pathophysiology, MainCategory::Physiology |
Sub Category | SubCategory::Endocrine |
Prompt | [[Prompt::A 56-year-old male is treated chronically with an antiarrhythmic drug. After several months the patient comes to the clinic complaining of difficulty with concentration, constipation, decreased libido and hair loss. On physical exam the doctor notices a bluish coloration of the skin that catches the physician attention, as it is the first time seeing this unique physical sign. Which of the following changes in the cardiac cell action potential mostly correlates to the drug being used?
|
Answer A | AnswerA::Decreases conduction velocity, increases the ERP and PR interval. |
Answer A Explanation | [[AnswerAExp::Incorrect. This mechanism corresponds to calcium channel blockers.]] |
Answer B | AnswerB::Decreases the AP duration, acts preferably on ischemic and depolarized ventricular tissue. |
Answer B Explanation | [[AnswerBExp::Incorrect. This mechanism corresponds to class IB sodium channel blockers.]] |
Answer C | AnswerC::Increases the AP duration & ERP. Increases the QT interval. Increases the Phase III. |
Answer C Explanation | [[AnswerCExp::Correct. This mechanism of action corresponds to Amiodarone]] |
Answer D | AnswerD::Increases AP duration, increases ERP, increases QT interval. Acts on both atria and ventricle. |
Answer D Explanation | [[AnswerDExp::Incorrect. This mechanism corresponds to class IA sodium channel blockers.]] |
Answer E | AnswerE::Decreases SA and AV nodal activity. Increases the PR interval. Decreases the slope of phase 4. |
Answer E Explanation | [[AnswerEExp::Incorrect. This corresponds to the mechanism of action of the beta blockers.]] |
Right Answer | RightAnswer::C |
Explanation | [[Explanation::Overall explanation: This patient is receiving an anti-arrhythmic which is causing hypothyroidism represented by: difficulty concentrating, constipation, decreased libido and hair loss. Amiodarone typically causes thyroid problems and bluish discolorations of the skin.
|
Approved | Approved::Yes |
Keyword | |
Linked Question | Linked:: |
Order in Linked Questions | LinkedOrder:: |